Latest news with #PacBio
Yahoo
6 days ago
- Business
- Yahoo
Target ALS Chooses PacBio HiFi Sequencing to Advance ALS Research with Largest Global Genomic Study to Date
Organization's 6,000-genome effort will power global ALS research through detailed long-read sequencing data made freely available to scientists worldwide NEW YORK and MENLO PARK, Calif., June 2, 2025 /PRNewswire/ -- Target ALS, a nonprofit breaking down barriers to amyotrophic lateral sclerosis (ALS) research, has partnered with PacBio (Nasdaq: PACB), a leading provider of high-quality, highly accurate long read sequencing platforms, to launch the largest global whole genome sequencing initiative for ALS to date. By applying PacBio's HiFi sequencing to more than 6,000 genomes from people with ALS and healthy controls, the project aims to detect structural variants, repeat expansions, and other hard-to-detect genetic features that may underlie the disease. As part of the ALS Global Research Initiative (AGRI), all data will be openly shared via the Target ALS Data Engine, removing barriers to access and enabling researchers around the world to uncover disease mechanisms and explore new pathways to treatment. The Importance of Long-Read Sequencing for ALS ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, gradually robbing individuals of muscle control and mobility. While genetic factors are known to play a role in some forms of ALS, much about the disease's origins and progression remains unknown. PacBio HiFi sequencing offers the resolution needed to detect these elements with greater confidence, particularly in non-coding regions of the genome, where regulatory disruptions may play a role in motor neuron degeneration. "90% of ALS patients do not know the cause of their disease. We are combining two powerful approaches to discover new genetic causes of ALS - the first is to go out into communities to generate data from as many people with ALS as we can find, particularly those who would not be able to come into clinic to participate in research, and the second is to use a method of sequencing that allows us to 'see' as much of the genome as is possible," says Dr. Amy Easton, Ph.D., Senior Director of Scientific Programs at Target ALS. Traditional short-read sequencing has helped identify known ALS-associated mutations, but its limited read length makes it difficult to resolve complex regions of the genome where novel variants may lie. Long-read sequencing, like PacBio's HiFi technology, captures DNA fragments ranging from 1,000 to 20,000 base pairs - compared to the 50 to 300 base pairs typical of short-read methods. This allows researchers to more accurately assemble genomes and view the full structure of genes and their regulatory elements. This comprehensive view is essential for ALS, where repeat expansions, cryptic splicing, and regulatory elements may all contribute to disease but often go undetected with short-read tools. In addition to providing access to longer swaths of DNA and accurate variant calls, HiFi data can be used to generate high-quality transcript isoform information and methylation profiles from each sample allowing researchers to examine how genetic variants may influence RNA expression and epigenetic changes in ALS. This integrated view has the potential to reveal novel disease mechanisms that are invisible to short-read sequencing approaches. "We're honored to support Target ALS in addressing one of the most urgent challenges in neurodegenerative disease," said David Miller, Vice President of Marketing at PacBio. "ALS has a complex genetic landscape marked by elements that are often missed with traditional sequencing. HiFi sequencing offers the length and accuracy needed to uncover those hidden regions, helping researchers make new connections between genetic variation and disease progression. By making these data broadly available, this project has the potential to accelerate discoveries that could lead to better diagnostics, new therapeutic targets, and ultimately, hope for people living with ALS." Driving Breakthroughs in ALS Research Through this collaboration, Target ALS is adding invaluable long-read sequencing data to their Data Engine, which already holds the most comprehensive collection of multi-omic datasets for ALS research. As with all Target ALS resources, access to the Data Engine is open to scientists worldwide at no cost. Whole genomes from this initiative are already available to be mined and analyzed. Together, Target ALS and PacBio continue to enrich this resource, performing short-read, long-read, and RNA sequencing on samples from AGRI, which includes a Global Natural History Study and Community Pop-up Clinics, and Target ALS' Postmortem Tissue Core. "For most researchers, the expense of long-read sequencing is prohibitive and the ability to obtain human samples is limited. Target ALS sees it as our role to continue to lower the barriers and fill the gaps, enabling rapid discovery of new diagnostic biomarkers and therapeutic targets," says Dr. Manish Raisinghani, M.B.B.S., Ph.D., Chief Executive Officer at Target ALS. To start mining the data, visit the Target ALS Data Engine. About Target ALS Target ALS is a medical research foundation breaking down barriers to Amyotrophic Lateral Sclerosis (ALS) research to find effective treatments. Since 2013, Target ALS has revolutionized ALS research through its Innovation Ecosystem. By democratizing research through an unbiased review process, providing access to cutting-edge research tools, facilitating cross-disciplinary collaboration, and galvanizing industry involvement, Target ALS accelerates the most promising ideas in scientific research into drug development programs. Driven by impatient optimism, deliberate disruption, and radical collaboration, Target ALS aims to transform ALS into a manageable disease, building a world where Everyone Lives. About PacBio PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our HiFi long-read sequencing and our SBB® short-read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit and follow @PacBio. PacBio products are provided for Research Use Only. Not for use in diagnostic procedures. Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to the uses, advantages, quality or performance of, the benefits or expected benefits of using, PacBio products or technologies, including in connection with Target ALS and its efforts to perform long-read sequencing of genomes from ALS patients; making the ALS genetic data available to scientists world-wide free of charge; intentions to examine how genetic variants includes expression and epigenetic changes in ALS; and other future events. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties that could cause actual outcomes and results to differ materially from currently anticipated results. These risks include, but are not limited to, risks inherent in identifying complicated genetic drivers of disease, including with respect to ALS; developing and commercializing new technologies; rapidly changing technologies and extensive competition in genomic sequencing; unanticipated increases in tariffs, costs or expenses; interruptions or delays in the supply of components or materials for, or manufacturing of, PacBio products and products under development; third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights; and other risks associated with general macroeconomic conditions and geopolitical instability. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption "Risk Factors." These forward-looking statements, including PacBio's preliminary unaudited financial information and PacBio's financial guidance, are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available. Contacts (Target ALS) Stephanie IshooManager, Research Communications and Marketing, Target Contacts (PacBio) Investors: Todd Friedmanir@ Media:pr@ View original content to download multimedia: SOURCE Target ALS
Yahoo
26-05-2025
- Business
- Yahoo
Asia-Pacific and Middle East NGS Market Research 2025-2035: Growing Prevalence of Non-Communicable Diseases, Advancement in the Performance of NGS Platforms
The Asia-Pacific and Middle East NGS market is witnessing substantial growth due to advances in NGS technology, rising genetic disorders and cancer cases, and expanding precision medicine applications. Key growth drivers include demand for personalized medicine, government initiatives, and innovation in sequencing platforms enhancing efficiency and cost-effectiveness. The market is dominated by countries like China, India, and Saudi Arabia, yet faces challenges such as high costs, data privacy issues, and a shortage of skilled professionals. Opportunities abound in rapidly developing economies, AI integration, and new NGS applications. Notable developments include new sequencing systems by PacBio and innovations by Illumina, emphasizing continuous industry advancements. Dublin, May 26, 2025 (GLOBE NEWSWIRE) -- The "Asia-Pacific and Middle East NGS Market: Focus on Offering, Platform, Throughput, Technology Type, Application, End User, and Country Analysis - Analysis and Forecast, 2025-2035" report has been added to Asia-Pacific and Middle East Next-Generation Sequencing (NGS) market is experiencing significant growth, driven by rapid advancements in next-generation sequencing technologies, the rising prevalence of genetic disorders and cancer, and the expanding application of next-generation sequencing in precision medicine. The Asia-Pacific and Middle East NGS market is highly consolidated, with around six key players accounting for a vast majority of the market share. Key players in the Asia-Pacific and Middle East NGS market analyzed and profiled in the study involve established and players that offer various kinds of NGS platforms, consumables, and services. Continuous innovations in next-generation sequencing platforms have enhanced efficiency, accuracy, and cost-effectiveness, making next-generation sequencing more accessible for both clinical diagnostics and research purposes. The increasing demand for next-generation sequencing in personalized medicine, particularly in oncology, reproductive health, and infectious disease diagnostics, is further fueling market expansion. Additionally, strong government initiatives, increased R&D investments, and strategic collaborations between biotech firms and healthcare providers are propelling the growth of next-generation sequencing in the region. Countries such as China, India, and Saudi Arabia are leading large-scale genomic projects to advance early disease detection and precision healthcare, further strengthening the Asia-Pacific and Middle East NGS market the strong growth potential of the next-generation sequencing market, several challenges persist. The high cost associated with next-generation sequencing platforms, consumables, and data analysis tools remains a major barrier, particularly in low-income regions. The shortage of skilled professionals proficient in bioinformatics and genomic data interpretation further hinders the widespread adoption of next-generation sequencing technologies. Moreover, concerns related to data privacy, security, and regulatory compliance create complexities in the implementation of next-generation sequencing across different countries. Additionally, variations in healthcare regulations and ethical concerns surrounding genomic data usage add to the market's constraints, making the adoption of next-generation sequencing more challenging in certain regions. This factor is posing a challenge for the Asia-Pacific and Middle East NGS the next-generation sequencing market in the Asia-Pacific and Middle East regions presents significant opportunities for expansion. Emerging economies with rapidly improving healthcare infrastructure are increasingly investing in next-generation sequencing research and clinical applications. The integration of artificial intelligence (AI) and cloud-based bioinformatics is revolutionizing genomic data analysis, making next-generation sequencing more efficient and accessible. Furthermore, the growing use of next-generation sequencing in non-invasive prenatal testing (NIPT) and infectious disease research offers new growth avenues for market players. As governments and private sector companies continue investing in genomic research, precision medicine, and clinical applications, the next-generation sequencing market in Asia-Pacific and the Middle East is poised for substantial expansion in the coming years. Market Dynamics The following are the drivers for the Asia-Pacific and Middle East NGS market: Increasing Adoption of NGS in Various Research and Diagnostics Fields Growing Prevalence of Non-Communicable Diseases Advancement in the Performance of NGS Platforms The market is expected to face some limitations as well due to the following challenges: Dearth of Skilled Professionals in Middle East Countries High Cost of Installation and Maintenance of the Equipment Reimbursement and Regulatory Policies of NGS Key Market Segmentation The Asia-Pacific and Middle East NGS market (by offerings) is expected to be dominated by the consumables segment. The Asia-Pacific and Middle East NGS market (by platform) is expected to be dominated by Illumina, Inc. The Asia-Pacific and Middle East NGS market (by throughput) is expected to be dominated by the high-throughput segment. The Asia-Pacific NGS market (by technology type) is expected to be dominated by the sequencing by synthesis segment. The Asia-Pacific NGS market (by application) is expected to be dominated by the translational research segment. The Asia-Pacific NGS market (by end user) is expected to be dominated by the academic and research insitutes segment. The Asia-Pacific NGS market (by country) is expected to be dominated by Japan and the Middle East NGS market (by country) is expected to be dominated by the U.A.E. Key Topics Covered:1. Asia-Pacific and Middle East NGS Market Overview1.1 Market Outlook1.1.1 Definitions1.1.2 Inclusion and Exclusion Criteria1.1.3 Market Size, 2024 - 2035, $Million1.1.4 Key Findings1.1.5 Market Growth Scenario1.1.5.1 Realistic Scenario1.1.5.2 Optimistic Scenario1.1.5.3 Pessimistic Scenario1.2 Industry Outlook1.2.1 NGS: Market Overview and Ecosystem1.2.2 Asia-Pacific and Middle East NGS: Overview1.2.3 Key Trends and Emerging Application of NGS in Asia-Pacific and Middle East1.2.4 Patent Analysis1.2.5 Pricing Analysis1.2.5.1 Instrument1.2.5.2 Consumables1.2.6 Supply Chain Analysis1.2.6.1 Key Entities in Supply Chain1.2.7 Regulatory Framework1.2.7.1 Asia-Pacific1.2.7.2 Middle East1.2.8 Genome Projects1.2.8.1 Asia-Pacific1.2.8.1.1 China1.2.8.1.2 Japan1.2.8.1.3 India1.2.8.1.4 South Korea1.2.8.1.5 Singapore1.2.8.1.6 Other Asian Countries1.2.8.2 Middle East1.2.8.2.1 UAE1.2.8.2.2 Qatar1.2.8.2.3 Saudi Arabia1.2.8.2.4 Kuwait1.2.8.2.5 Other Middle East Countries1.3 Market Dynamics1.3.1 Market Drivers1.3.1.1 Impact Analysis1.3.2 Market Restraints1.3.2.1 Impact Analysis1.3.3 Market Opportunities2. Asia-Pacific and Middle East NGS Market Analysis (By Offering), $Million, 2024-20352.1 Consumables2.1.1 Library Preparation and Reagents2.1.2 Sequencing Kits and Reagents2.1.3 Others2.2 Equipment2.3 Services2.3.1 Sequencing Services2.3.2 Data Management Services3. Asia-Pacific and Middle East NGS Market Analysis (By Workflow), $Million, 2024-20353.1 Sequencing3.2 Pre-Sequencing3.3 Data Analysis4. Asia-Pacific and Middle East NGS Market Analysis (By Platform), $Million, 2024-20354.1 Overview4.1.1 Asia-Pacific4.1.2 Middle East4.2 Illumina, Inc. (Asia-Pacific and Middle East)4.3 Thermo Fisher Scientific, Inc. (Asia-Pacific and Middle East)4.4 Pacific Biosciences of California, Inc. (Asia-Pacific and Middle East)4.5 Oxford Nanopore Technologies plc. (Asia-Pacific and Middle East)4.6 Other Companies (Asia-Pacific and Middle East)5. Asia-Pacific and Middle East NGS Market Analysis (By Throughput), $Million, 2024-20355.1 Overview5.1.1 Asia-Pacific5.1.2 Middle East5.2 High-Throughput5.3 Medium-Throughput5.4 Low-Throughput6. Asia-Pacific and Middle East NGS Market Analysis (By Technology Type), $Million, 2024-20356.1 Sequencing by Synthesis6.2 Ion Torrent Semiconductor Sequencing6.3 Single Molecule Real-time Sequencing6.4 Nanopore Sequencing Technologies6.5 Other Technologies7. Asia-Pacific and Middle East NGS Market Analysis (By Application), $Million, 2024-20357.1 Clinical Diagnostics7.1.1 Oncology7.1.2 Infectious Diseases7.1.3 Reproductive Genetics7.1.4 Others7.2 Translational Research7.2.1 Clinical7.2.2 Agricultural7.2.3 Others8. Asia-Pacific and Middle East NGS Market Analysis (By End User), $Million, 2024-20358.1 Pharmaceutical and Biotechnology Companies8.2 Academic and Research Institution8.3 Clinical Laboratories8.4 Others9. Asia-Pacific NGS Market Analysis (By Country), $Million, 2024-20359.1 Market Overview9.2 Market Sizing and Forecast9.2.1 Japan9.2.2 China9.2.3 India9.2.4 South Korea9.2.5 Australia9.2.6 Singapore9.2.7 New Zealand9.2.8 Rest of Asia-Pacific10. Middle East NGS Market Analysis (By Country), $ Million, 2024-203510.1 Market Overview10.2 Market Sizing and Forecast10.2.1 UAE10.2.2 KSA10.2.3 Israel10.2.4 Egypt10.2.5 Rest-of-Middle East11. Asia-Pacific and Middle East NGS Market - Competitive Benchmarking and Company Profiles11.1 Competitive Benchmarking11.2 Competitive Landscape11.2.1 Key Strategies and Developments by Company11.2.1.1 Funding Activities11.2.1.2 Mergers and Acquisitions11.2.1.3 Regulatory Approvals11.2.1.4 Partnerships, Collaborations, and Business Expansions11.2.2 Market Share Analysis, 2024-203511.2.3 Growth Share Analysis for Asia-Pacific and Middle East NGS Market (by End User)11.2.4 Growth Share Analysis for Asia-Pacific and Middle East NGS Market (by Throughput)11.3 Company Profiles11.4 Emerging Companies (Asia-Pacific and Middle East)Companies Featured BGI Group Illumina, Inc. Thermo Fisher Scientific Inc. Pacific Biosciences of California, Inc. Oxford Nanopore Technologies plc. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23-05-2025
- Business
- Yahoo
PacBio Stock Slips Despite New China Distribution Deal With Haorui
PacBio PACB recently announced a key distribution agreement with Haorui Gene, a globally recognized leader in blood typing genomics. This strategic partnership grants PacBio access to a wider clinical laboratory network across China, accelerating the adoption of its HiFi sequencing technology. Haorui Gene, known for its expertise in genomic solutions and extensive reach within the clinical diagnostics ecosystem, will serve as an important channel partner to promote PacBio's advanced long-read sequencing platforms. Through this collaboration, PacBio aims to meet the growing demand for high-accuracy genomic sequencing in China, particularly in clinical research and precision medicine applications. By leveraging Haorui Gene's distribution capabilities and relationships with top-tier laboratories, PacBio is well-positioned to support more comprehensive and precise genomic analysis. Following the announcement, shares of the company closed flat at $1.12 on Friday. In the year-to-date period, PACB's shares have lost 48.6% compared with the industry's 9.7% decline. The S&P 500 decreased 1.2% in the same time frame. The deal with Haorui Gene positions PacBio for long-term growth by expanding its reach into China's vast clinical diagnostics market, enabling broader adoption of its HiFi sequencing technology. Through Haorui's extensive lab network, PacBio can drive recurring revenue from consumables and services while accelerating its footprint in one of the world's largest genomics markets. This strategic move not only boosts technology adoption but also strengthens PacBio's role in advancing precision medicine across Asia, laying the groundwork for future partnerships and population-scale initiatives. Meanwhile, PACB currently has a market capitalization of $294.4 million. The company expects its earnings to grow 16.8% in 2025. Image Source: Zacks Investment Research PacBio's newly formalized distribution agreement with Haorui Gene is focused on accelerating the adoption of HiFi long-read sequencing technology across clinical and research settings in China, particularly in transfusion medicine and hematology. These are fields where comprehensive, accurate genomic data is vital to improving patient outcomes. The partnership is designed to make PacBio's HiFi sequencing the preferred solution for analyzing highly polymorphic genomic regions, structural variants, and full-length genes, areas critical for safe blood transfusions, precise donor-recipient matching, and the identification of rare blood types. Haorui Gene, founded in 2020, has rapidly emerged as a leader in blood typing genomics in China. The company operates seven Sequel II and three Revio systems to support national initiatives in HLA typing, blood group genotyping, and rare blood type discovery. Through its work, Haorui has demonstrated that long-read sequencing can provide unparalleled resolution in genomically complex regions, surpassing the capabilities of traditional short-read technologies. The company has already contributed to over 20 peer-reviewed publications and has seen widespread adoption of its approaches across Chinese blood centers, establishing itself as a trusted player in precision hematology. Under the agreement, Haorui Gene will likely distribute PacBio's full product suite, including the Vega platform, delivering comprehensive, end-to-end solutions for clinical labs, genomics institutions, and blood centers. This supports national initiatives like erythrocyte antigen mapping and rare blood type classification, which require high-resolution, allele-level insights. Haorui's rollout of HiFi-based HLA typing in 2022 and blood group panels in 2023 highlights growing momentum in long-read sequencing. The partnership aims to scale access to PacBio's technology and establish it as a cornerstone of personalized medicine and clinical diagnostics in China's rapidly expanding genomics market. Per a report by Grand View Research, the global long-read sequencing market size was estimated at $538.9 million in 2024 and is expected to witness a CAGR of 20.12% from 2025 to 2030. The major factors driving the market growth include the rising prevalence of genetic diseases, such as cancers and chromosomal disorders, the rising popularity of personalized medicine, and rising technological advancements resulting in the emergence of newer technologies, such as third-generation sequencing. PACB carries a Zacks Rank #3 (Hold) at present. Some better-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation CVS, Integer Holdings Corporation ITGR and AngioDynamics ANGO. CVS Health, carrying a Zacks Rank of 2 (Buy), reported first-quarter 2025 adjusted earnings per share (EPS) of $2.25, beating the Zacks Consensus Estimate by 31.6%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Revenues of $94.59 billion outpaced the consensus mark by 1.8%. CVS Health has a long-term estimated growth rate of 11.4%. Its earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%. Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank #1. Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%. AngioDynamics, currently sporting a Zacks Rank #1, reported a third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a 13-cent loss. Revenues of $72 million beat the Zacks Consensus Estimate by 2%. ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 Composite's 10.5% growth. AngioDynamics' earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 70.9%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report Pacific Biosciences of California, Inc. (PACB) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
13-05-2025
- Business
- Yahoo
PACB Stock May Rise Following the Deal With Chulalongkorn University
PacBio PACB recently announced a strategic collaboration with Chulalongkorn University, one of Thailand's foremost institutions in genomic and translational research, to implement PacBio's HiFi whole genome sequencing (WGS) as part of the newborn screening research program. This initiative marks the first population-scale deployment of PacBio's HiFi technology in the Asia Pacific region. It is designed to evaluate how comprehensive genomic data can enable earlier and more accurate identification of rare, treatable conditions in newborns. By integrating PacBio's advanced long-read sequencing capabilities, the program will help uncover a broader spectrum of genetic variants that often go undetected with traditional screening methods. Through this effort, PacBio and Chulalongkorn University aim to build a scalable model that could transform early-stage diagnostics and public health planning on a global scale. Following the announcement, shares of the company closed flat at $1.12 on Friday. In the year-to-date period, PACB's shares have lost 38.8% compared with the industry's 10.1% decline. The S&P 500 decreased 4.4% in the same time frame. This collaboration positions PacBio at the forefront of a major shift in global healthcare, signaling growing adoption of its HiFi sequencing technology for large-scale clinical applications. By demonstrating real-world utility in a critical use case, such as newborn screening, PacBio not only expands its footprint in the fast-growing Asia Pacific region but also builds a compelling case for broader international adoption. Successful implementation could lead to long-term revenue growth from government contracts, public health partnerships, and increased demand for HiFi systems, reinforcing investors' confidence in the scalability and relevance of PacBio's platform in precision medicine. Meanwhile, PACB currently has a market capitalization of $336.1 million. The company expects its earnings to grow 13.1% in 2025. Image Source: Zacks Investment Research The collaboration between PacBio and Chulalongkorn University is a landmark initiative that highlights the transformative potential of WGS in public health. Traditional newborn screening programs typically rely on targeted panels to detect a limited number of conditions, often missing rare or complex genetic disorders. PacBio's HiFi WGS, by contrast, delivers highly accurate, long-read genomic data that captures regions of the genome inaccessible to short-read technologies. This includes structural variants, repeat expansions, and epigenomic information, all of which are critical for identifying a wider spectrum of genetic risks from birth. By enabling a more complete and precise view of the newborn genome, the technology opens the door to earlier diagnosis and intervention for conditions that might otherwise remain undetected until much later in life. Chulalongkorn University, through its Center of Excellence for Medical Genomics, is likely to bring deep expertise and infrastructure to the table, making it an ideal partner for this endeavor. The university aims to build a robust and scalable research model that can be replicated across other national health systems. This research-driven approach not only enhances clinical care but also contributes to public health data systems, laying the groundwork for informed policy decisions, better resource allocation, and eventually, personalized healthcare strategies on a national scale. On a broader level, this initiative positions Thailand as a leader in precision medicine within the Asia Pacific region and places PacBio at the center of a growing global movement toward genome-informed healthcare. By successfully deploying HiFi WGS in a population-scale screening program, PacBio is setting a benchmark for how advanced sequencing technologies can be integrated into public health. This could catalyze similar initiatives in other countries, unlocking new markets and reinforcing PacBio's reputation as a pioneer in genomic innovation. With increasing recognition of genomics as a foundational tool in early disease detection and prevention, this collaboration not only accelerates scientific progress but also enhances PacBio's long-term commercial and strategic outlook. Per a report by Grand View Research, the global whole genome sequencing market size was estimated at $2.12 billion in 2024 and is expected to witness a CAGR of 22.17% from 2025 to 2030. The WGS market is experiencing significant growth, driven by a confluence of technological advancements, decreasing costs, and a growing demand for personalized medicine. Several key factors contribute to this expansion, transforming the landscape of genomics and impacting various sectors, including healthcare, research, and agriculture. PACB carries a Zacks Rank #3 (Hold) at present. Some better-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation CVS, Integer Holdings Corporation ITGR and Boston Scientific Corporation BSX. CVS Health, carrying a Zacks Rank of 2 (Buy), reported first-quarter 2025 adjusted EPS of $2.25, beating the Zacks Consensus Estimate by 31.6%. Revenues of $94.59 billion outpaced the consensus mark by 1.8%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. CVS Health has a long-term estimated growth rate of 11.4%. CVS's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.1%. Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank #1. Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%. Boston Scientific reported first-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 11.9%. Revenues of $4.66 billion surpassed the Zacks Consensus Estimate by 2.3%. It currently carries a Zacks Rank #2. Boston Scientific has a long-term estimated growth rate of 13.3%. BSX's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.8%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report Pacific Biosciences of California, Inc. (PACB) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12-05-2025
- Business
- Yahoo
PacBio Board Independent Investigation Concludes Allegations Unsubstantiated
MENLO PARK, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced that the Special Committee of its Board of Directors (the 'Special Committee') has concluded its independent investigation into previously disclosed allegations from an attorney representing an employee impacted by our recent reduction in force regarding certain employment practices and cybersecurity matters of the Company. The allegations did not involve the current, or any previously reported, financial results, and the investigation found no improper employment practices and no material inaccuracies or omissions with respect to the cybersecurity disclosures in the Company's 2024 Form 10-K. Chairman of the Board John Milligan said, 'We are pleased to have this investigation behind us and look forward to continuing to fulfill our mission of enabling the promise of genomics to better human health.' About PacBio PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit and follow @PacBio. PacBio products are provided for Research Use Only. Not for use in diagnostic procedures. Forward-Looking StatementsThis press release contains 'forward-looking statements' within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties and could cause actual outcomes and results to differ materially from currently anticipated results. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption 'Risk Factors.' These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available. Contacts Investors:Todd Friedmanir@ Media:pr@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
